What's Happening?
Atom Therapeutics, a biotechnology company focused on metabolic and inflammatory diseases, will present updates on its clinical trials at the BIO International Convention 2026 in San Diego. The company is advancing two lead drugs: Lingdolinurad (ABP-671),
a URAT1 inhibitor for chronic gout, and ABP-745, an anti-inflammatory drug for acute gout flares. Lingdolinurad is in Phase 3 trials in China and will soon enter international trials, including in the U.S. ABP-745 has shown promising safety and efficacy in Phase 2 trials for acute gout and is also being tested for atherosclerotic cardiovascular disease. The presentation will be led by Roy J. Wu, Senior Vice President for Global Business Development.
Why It's Important?
The development of new treatments for gout and related inflammatory conditions addresses a significant unmet medical need, as current therapies often have limited efficacy and safety concerns. Atom Therapeutics' focus on innovative small molecule drugs could provide more effective and safer options for patients suffering from chronic and acute gout. The company's progress in clinical trials and its participation in the BIO International Convention highlight its commitment to advancing these therapies on a global scale. Successful outcomes from these trials could lead to new standards of care and improve the quality of life for patients with these debilitating conditions.
What's Next?
Atom Therapeutics plans to continue its clinical trials, with upcoming data readouts expected to provide further insights into the efficacy and safety of its lead compounds. The company may also seek regulatory approvals and partnerships to facilitate the commercialization of its drugs. As the trials progress, Atom Therapeutics could expand its research into additional indications, such as pericarditis and heart failure, leveraging its expertise in inflammatory and metabolic diseases. The outcomes of these efforts could significantly impact the treatment landscape for gout and related conditions.
